News

Huntington’s Disease ‘Gene Silencing’ Drug Given to First Human Patients

October 19, 2015, marks a historical day in the treatment of Huntington’s Disease. At University College London Hospitals, patients afflicted with the degenerative neurological condition that day received an innovative new “gene silencing” drug. There is great hope that this drug will revolutionize the treatment of this destructive disease, for which there is currently…

Huntingtin Protein Study Offers New Insights into Mystery of Huntington’s Disease

University of Buffalo researchers have discovered that Huntingtin protein (Htt) is involved in the transport of Rab proteins, which are essential for normal cell function, a discovery that might lead to a greater understanding of the mechanisms behind Huntington’s disease. The research paper entitled “Huntingtin differentially regulates the axonal transport of a sub-set…

Anti-Epileptic Drug Shows Potential in Neurodegenerative Diseases

In a new study titled “Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression”, published in Molecular Neurodegeneration, researchers have discovered that ethosuximide, a commonly prescribed anti-epileptic drug, has protective and potential therapeutic effects for neurodegenerative diseases, such as Parkinson’s, Alzheimer’s and Huntington’s. To investigate the…

Houston Methodist Calls Attention to Movement Disorders

While moving is normal to healthy people, making even the smallest movements may seem a difficult task for those who suffer from movement disorders such as Huntington’s disease. The Houston Methodist Sugar Land Hospital is spreading awareness about these types of conditions and their proper treatment, the importance of seeking professional help…

Songbirds Could Be Used as Valuable Tool to Study Brain Neurodegeneration, Huntington’s Disease

In a recent paper published in Nature Neuroscience journal entitled “Human mutant huntingtin disrupts vocal learning in transgenic songbirds“, Rockefeller University researchers reported that songbirds could be used as new tool to study Huntington’s disease (HD), providing a more complete understanding of the mechanisms underlying brain neurodegeneration.

Cloud Pharmaceuticals and THERAMetrics Partner to Develop Treatments for Orphan CNS Diseases

Cloud-based drug design and development company, Cloud Pharmaceuticals, Inc., recently announced it has signed with THERAMetrics holding AG to collaborate on breakthrough treatments for orphan central nervous system (CNS) diseases and other indications. This strategic collaboration has as its primary points of interest Huntington’s disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy…